. Delon, Mise en évidence des difficultés liées à l'utilisation des chimiothérapies anticancéreuses orales : exploitation des bases de données médico-administratives de l'Assurance Maladie, 2017.

D. Sur,

A. Laugueux, P. Legendre, L. Fetique, R. Bellay, and P. Menard, Consultations pharmaceutiques chez des patients traités par chimiothérapie orale, vol.35, p.6, 2019.

, Recommandations SFPO sur la réalisation de consultations pharmaceutiques en oncologie, 2017.

C. Fitzmaurice, D. Dicker, A. Pain, H. Hamavid, and M. Moradi-lakeh, The Global Burden of Cancer, JAMA Oncol, vol.1, issue.4, pp.505-532, 2013.

A. Ribed, R. M. Romero-jiménez, V. Escudero-vilaplana, I. Iglesias-peinado, and A. Herranz-alonso, Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction, Int J Clin Pharm, vol.38, issue.2, pp.280-288, 2016.

, Données globales d'épidémiologie des cancers -Epidémiologie des cancers

D. Sur,

, Fondation pour la Recherche Médicale

E. Peyrilles, C. Lepage-seydoux, K. Sejean, and B. Bonan, Mise en place d'un programme de suivi à distance des patients atteints de cancer et traités par chimiothérapie en hôpital de jour : un enjeu de taille pour les différents acteurs, Bull Cancer (Paris), vol.105, issue.4, pp.357-67, 2018.

. Has-inca, La conciliation des traitements médicamenteux en cancérologie, 2019.

L. Tohic and S. , Intérêt du dossier pharmaceutique lors de la rétrocession dans un Centre de Lutte Contre le Cancer, 2018.

L. Colombo, P. M. Aguiar, T. M. Lima, and S. Storpirtis, The effects of pharmacist interventions on adult outpatients with cancer: A systematic review, J Clin Pharm Ther, vol.42, issue.4, pp.414-438, 2017.

, Institut publie L'essentiel des faits et chiffres des cancers en France (édition 2019) -Actualités

, Population par âge ? Tableaux de l'économie française | Insee

D. Sur,

, Pyramide des âges | Insee

D. Sur,

, American cancer society. Global Cancer Facts & Figures, vol.60, 2011.

, Cancer et médecines complémentaires : vers une nouvelle cohabitation, 2014.

, Une étude montre la progression du taux de survie aux trois cancers les plus fréquents en France

S. Occhipinti, E. Petit-jean, F. Pinguet, C. Beaupin, and M. Daouphars, Implication du pharmacien dans l'accompagnement des patients sous anticancéreux oraux : état des lieux dans les centres de lutte contre le cancer (CLCC), Bull Cancer, vol.104, issue.9, pp.727-761, 2017.

S. Renet, C. Maritaz, J. Lotz, S. Burnel, and P. Paubel, Parcours de soins : modélisation et analyse des risques induits par les anticancéreux oraux, Bulletin du cancer, 2016.

N. Janodet, Education therapeutique et traitements anticancereux oraux analyse de besoins des patients et des professionnels de sante au Centre Leon Berard, 2018.

B. A. Given, S. L. Spoelstra, and M. Grant, The Challenges of Oral Agents as Antineoplastic Treatments, Semin Oncol Nurs, vol.27, issue.2, pp.93-103, 2011.

C. Dorlean, V. Perron, A. Bertaut, A. Lagrange, and A. Schmitt, Sécurisation et optimisation de la prise en charge des patients en cancérologie, Soins Cadres, vol.27, issue.107, pp.34-41, 2018.

J. Cassidy, Benefits and Drawbacks of the Use of Oral Fluoropyrimidines as Single-Agent Therapy in Advanced Colorectal Cancer, Clinical Colorectal Cancer, 2005.

C. Streicher and A. Daulange, Implementation of pharmacist consultations as part of a multidisciplinary consultation program for patients with oral anticancer agent: A descriptive study, Eur J Oncol Pharm, vol.1, issue.2, p.3, 2018.

J. Aisner, Overview of the changing paradigm in cancer treatment: oral chemotherapy, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm, vol.64, issue.9, pp.4-7, 2007.

S. Faithfull and P. Deery, Implementation of capecitabine (Xeloda®) into a cancer centre: UK experience, Eur J Oncol Nurs, vol.8, pp.54-62, 2004.

M. Findlay, G. Von-minckwitz, and A. Wardley, Effective oral chemotherapy for breast cancer: pillars of strength, Ann Oncol, vol.19, issue.2, pp.212-234, 2008.

F. Bassan, F. Peter, B. Houbre, M. J. Brennstuhl, and M. Costantini, Adherence to oral antineoplastic agents by cancer patients: definition and literature review, Eur J Cancer Care (Engl). janv, vol.23, issue.1, pp.22-35, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01798969

J. Sicard and F. Veron, Pour une prise en charge pluriprofessionnelle centrée sur le patient cancéreux, Actual Pharm, vol.58, issue.584, pp.40-45, 2019.

F. M. Palmieri and D. L. Barton, Challenges of Oral Medications in Patients With Advanced Breast Cancer, Semin Oncol Nurs, vol.23, pp.17-22, 2007.

G. Liu, E. Franssen, M. I. Fitch, and E. Warner, Patient preferences for oral versus intravenous palliative chemotherapy, J Clin Oncol, 2016.

N. Shah, E. Casella, D. Capozzi, S. Mcgettigan, and T. Gangadhar, Improving the safety of oral chemotherapy at an Academic Medical Center, 2016.

N. Vantard, F. Rancho, V. Schwiertz, C. Gourc, and N. Gauthier, EPICC study evaluation of pharmaceutical intervention in cancer care, Journal of clinical pharmacy and therapeutics, 2015.

M. Babin, C. Folliard, J. Robert, J. Sorrieul, and H. Kieffer, Consultations pharmaceutiques en oncologie mise en place, bilan à un an et perspectives. Annales pharmaceutiques francaises, 2019.

A. Bourmaud, E. Hénin, F. Tinquaut, V. Regnie, and C. Hamant, Observance d'une chimiothérapie orale : identification des profils de patientes grâce à une analyse des correspondances multiples et des entretiens (Étude OCTO-SOCIO), Rev DÉpidémiologie Santé Publique, vol.62, p.145, 2014.

, Drug Interactions With Commonly Prescribed Oral Chemotherapeutic and Targeted Agents. Top issues, 2011.

V. Regnier-denois, J. Poirson, S. Pouyalet, F. Chauvin, and F. , La chimiothérapie par voie orale: représentations et pratiques des oncologues et des patients, Psycho-Oncol, vol.3, issue.3, pp.168-75, 2009.

S. N. Weingart, J. Flug, D. Brouillard, L. Morway, and A. Partridge, Oral chemotherapy safety practices at US cancer centres: questionnaire survey, BMJ, vol.334, issue.7590, p.407, 2007.

S. N. Weingart, E. Brown, P. Bach, K. Eng, and S. Johnson, NCCN task force report : oral chemotherapy, J Natl Compr Canc Netw, vol.6, p.25, 2008.

F. Oncolien and S. Capécitabine,

D. Sur,

S. Wong, M. Bounthavong, C. Nguyen, K. Bechtoldt, and E. Hernandez, Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic, Am J Health Syst Pharm, vol.71, issue.11, pp.960-965, 2014.

C. Rioufol, L'observance Comment la mesurer et l'améliorer. 12ème Biennale Monégasque de Cancérologie, 2016.

C. Rioufol, Lettre d'intention pour le projet d'expérimentation d'innovation en santé Oncoral -Projet de loi de financement de la sécurité sociale 2018 -Article 51, 2018.

, Livre Blanc des Hémopathies malignes Version Numerique version, 2016.

. Mésusage,

S. Ministère-des, L. De, and . Santé,

D. Sur,

. Iatrogénie,

S. Ministère-des, L. De, and . Santé,

D. Sur,

D. Sur,

R. W. Van-leeuwen, E. L. Swart, F. A. Boom, M. S. Schuitenmaker, and J. G. Hugtenburg, Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method, BMC Cancer, vol.10, issue.1, p.679, 2010.

A. Ribed, R. Romero-jimenez, V. Escudero-vilaplana, I. Iglesias-peinado, and A. Herranz-alonso, Pharmaceutical care program for onco-hematologic outpatients : safety, efficiency and patient satisfaction, Int J Clin Pharm, 2016.

C. Walter, J. Mellor, C. Rice, S. Kirsa, and D. Ball, Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic, Journal of clinical oncology, 2016.

R. Van-leeuwen, E. L. Swart, F. A. Boom, M. S. Schuitenmaker, and J. G. Hugtenburg, Potential drug interactions and duplicate prescriptions among ambulatory cancer patients : a prevalence study using an advanced screening method. BMC Cancer, 2010.

C. Lopez-martin, G. Siles, M. , A. , J. et al., Role of clinical pharmacists to prevent drug interactions in cancer outpatients : a single-center experience, Int J Clin Pharm, 2014.

R. Van-leeuwen, D. Brundel, C. Neef, T. Van-gelder, R. Mathijssen et al., Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs, Br J Cancer, vol.108, issue.5, pp.1071-1079, 2013.

C. Lopez-martin, G. Siles, M. , A. , J. et al., Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience, Int J Clin Pharm. déc, vol.36, issue.6, pp.1251-1260, 2014.

C. Maritaz, N. Gault, C. Roy, F. Tubach, and S. Burnel, Impact d'une organisation régionale coordonnée pour sécuriser la prise en charge des patients sous anticancéreux oraux : CHIMORAL, une étude comparative, Bull Cancer, vol.106, issue.9, pp.734-780, 2019.

, Common Terminology Criteria for Adverse Events

D. Sur,

. Cepd_toxicite and . Pdf,

D. Sur,

R. J. Maggiore, W. Dale, C. P. Gross, T. Feng, and W. P. Tew, Polypharmacy and Potentially Inappropriate Medication Use in Older Adults with Cancer Undergoing Chemotherapy: Effect on Chemotherapy-Related Toxicity and Hospitalization During Treatment, J Am Geriatr Soc, vol.62, issue.8, pp.1505-1517, 2014.

T. Zhou, J. Duan, G. Zhou, J. Cai, and Z. Huang, Impact of Depression Mood Disorder on the Adverse Drug Reaction Incidence Rate of Anticancer Drugs in Cancer Patients, J Int Med Res, vol.38, issue.6, pp.2153-2162, 2010.

H. Wu, H. Wei, and F. Xu, Pharmacist-led nonpharmacological intervention in cancer chemotherapy, Patient Educ Couns, vol.98, issue.2, p.265, 2015.

G. Dumas and E. Canet, Effets cardiovasculaires graves des chimiothérapies, thérapies ciblées et des traitements immunosuppresseurs. Réanimation, vol.25, issue.S3, pp.123-159, 2016.

, Effets secondaires -Chimiothérapie

D. Sur,

G. I. Köhler, S. M. Bode-böger, R. Busse, M. Hoopmann, and T. Welte, Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use, Int J Clin Pharmacol Ther, vol.38, issue.11, pp.504-517, 2000.

P. Aubin, K. Cloutier, F. Dubé, D. Lebel, and E. Ferreira, La mesure de l'observance du traitement, la technologie au service du pharmacien et du patient, Pharmactuel, vol.8, 2005.

K. Ruddy, E. Mayer, and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA Cancer J Clin, vol.59, issue.1, pp.56-66, 2009.

W. Geynisman, Adherence to Targeted Oral Anticancer Medications, Discov Med, vol.15, issue.83, pp.231-272, 2013.

Y. Lwern-yap, K. , S. See, C. Chan, and A. , Clinically relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer, 2010.

J. M. Jacobs, N. A. Pensak, N. J. Sporn, J. J. Macdonald, and I. T. Lennes, Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer, J Oncol Pract, vol.13, issue.5, pp.474-85, 2017.

F. Despas, H. Roche, and G. Laurent, Anticancer drug adherence, Bull Cancer (Paris), vol.100, issue.5, pp.473-84, 2013.

L. Huiart, V. Bardou, and G. R. , L'adhésion thérapeutique aux traitements oraux : enjeux en oncologie -l'exemple du cancer du sein, Bull Cancer (Paris), vol.100, issue.10, pp.1007-1022, 2015.

V. Ziller, M. Kalder, U. Albert, W. Holzhauer, and M. Ziller, Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer, Ann Oncol Off J Eur Soc Med Oncol, vol.20, issue.3, pp.431-437, 2009.

J. A. Greer, N. Amoyal, L. Nisotel, J. N. Fishbein, and J. Macdonald, A Systematic Review of Adherence to Oral Antineoplastic Therapies, The Oncologist, vol.21, issue.3, pp.354-76, 2016.

C. Gelas, Implication du pharmacien hospitalier dans la prise en charge des patients sous anticancéreux oraux: expérience au Centre Hospitalier de Brive-la-Gaillarde, 2019.

C. Streicher, V. Servant, A. Berroneau, F. Xuereb, and S. Djabarouti, La conciliation médicamenteuse pour renforcer le lien ville-hôpital, Pharm Hosp Clin, vol.49, issue.2, pp.45-51, 2014.

F. Ranchon, C. Bouret, B. Charpiat, and G. Leboucher, Sécurisation de l'emploi des chimiothérapies anticancéreuses administrables par voie orale, 2009.

R. Abbott, S. Edwards, M. Whelan, J. Edwards, and G. Dranitsaris, Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada, J Oncol Pharm Pract, 2013.

P. Renard, Délivrance des anticancéreux oraux : besoins et attentes du pharmacien d'officineDelivery of oral anticancer agents: requirements and expectations of the pharmacist, vol.52, 2013.

, Prise en charge des patients

. Onco-nouvelle-aquitaine,

C. Enfants--oncopédiatrie-|-réseau-régional-de and . Oncopaca-corse,

D. Sur,

, Matrice d'habilitation des professionnels de santé pour le DMP, DMP : Dossier Médical Partagé

D. Sur,

, Épidémiologie des cancers chez les patients de 65 ans et plus -Oncogériatrie

D. Sur,

B. D. Smith, G. L. Smith, A. Hurria, G. N. Hortobagyi, and T. A. Buchholz, Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation, J Clin Oncol, vol.27, issue.17, pp.2758-65, 2009.

E. Cayet and T. Maréchal, Création d'un site Internet pour la mise à disposition d'un livret thérapeutique des médicaments appropriés aux personnes âgées, à l'intention des EHPAD, 2017.

M. Bourgouin, Evaluation du risque de prescriptions inappropriées chez le sujet âgé atteint de cancer, 2013.

S. Legrain, Consommation Médicamenteuse chez le Sujet Agé, vol.16, 2005.

K. Sokol, J. Knudsen, and M. Li, Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management, Journal of clinical pharmacy and therapeutics, 2007.

V. Schwiertz, C. Bertin, A. Henry, and B. Charpiat, Estimation du nombre et de la nature des interactions médicamenteuses concernant les médicaments anticancéreux, Bull Cancer (Paris), vol.94, issue.5, pp.477-82, 2007.

J. H. Lewis, M. L. Kilgore, D. P. Goldman, E. L. Trimble, and R. Kaplan, Participation of patients 65 years of age or older in cancer clinical trials, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, issue.7, pp.1383-1392, 2003.

J. Herrstedt, Optimal antineoplastic therapy and supportive care of elderly cancer patients, OncologyPRO, 2018.

R. J. Maggiore, C. P. Gross, and A. Hurria, Polypharmacy in Older Adults with Cancer, The Oncologist, vol.15, issue.5, pp.507-529, 2010.

A. Whitman, K. Degregory, A. Morris, S. Mohile, and E. Ramsdale, Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study, Support Care Cancer, vol.26, issue.12, pp.4105-4118, 2018.

G. Questionnaire,

D. Sur,

G. Filtre-onco,

S. Tuna, O. Dizdar, and M. Calis, The prevalence of usage of herbal medicines among cancer patients, vol.4, 2013.

C. Morandini, La place des médecines complémentaires chez les patients sous chimiothérapie : étude prospective multicentrique réalisée auprès des patients et des professionnels de santé de cancérologie dans 4 hôpitaux de la région, 2012.

A. Molassiotis, V. Panteli, E. Patiraki, G. Ozden, and N. Platin, Complementary and alternative medicine use in lung cancer patients in eight European countries, Complement Ther Clin Pract, vol.12, issue.1, pp.34-43, 2006.

C. Massat, Prévalence des interactions médicamenteuses avec les anticancéreux oraux : exemple des thérapies ciblées du cancer du sein, 2015.

H. S. Boon, F. Olatunde, and S. M. Zick, Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from, BMC Womens Health, vol.7, p.4, 1998.

A. Molassiotis, P. Fernández-ortega, D. Pud, G. Ozden, and J. A. Scott, Use of complementary and alternative medicine in cancer patients: a European survey, Ann Oncol Off J Eur Soc Med Oncol, vol.16, issue.4, pp.655-63, 2005.

S. Träger-maury, C. Tournigand, F. Maindrault-goebel, P. Afchain, A. Gramont et al., Utilisation de médecine complémentaire chez les patients atteints de cancer dans un service de cancérologie français, Bull Cancer, vol.94, issue.11, pp.1017-1042, 2007.

L. Simon, D. Prebay, A. Beretz, J. Bagot, and A. Lobstein, Médecines complémentaires et alternatives suivies par les patients cancéreux en France, Bull Cancer, vol.94, issue.5, pp.483-491, 2007.

A. Ramos-esquivel, Á. Víquez-jaikel, and C. Fernández, Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance, J Oncol Pract, vol.13, issue.7, pp.613-635, 2017.

J. S. Mccune, A. J. Hatfield, A. Blackburn, P. O. Leith, and R. B. Livingston, Potential of chemotherapy?herb interactions in adult cancer patients, Support Care Cancer, vol.12, issue.6, pp.454-62, 2004.

, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers | Oncology | JAMA Oncology | JAMA Network, Complementary Medicine

A. Liekweg, M. Westfeld, and U. Jaehde, From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.12, pp.73-82, 2004.

L. M. Holle, B. Michaud, and L. , Oncology Pharmacists in Health Care Delivery: Vital Members of the Cancer Care Team, J Oncol Pract, vol.10, issue.3, pp.142-147, 2014.

J. M. Patel, L. M. Holle, J. M. Clement, T. Bunz, and C. Niemann, Impact of a pharmacist-led oral chemotherapymonitoring program in patients with metastatic castrate-resistant prostate cancer, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract, vol.22, issue.6, pp.777-83, 2016.

C. Walter, J. D. Mellor, C. Rice, S. Kirsa, and D. Ball, Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic: Pharmacist in lung cancer clinic, Asia Pac J Clin Oncol, vol.12, issue.3, pp.367-74, 2016.

V. Lamy, C. Rey, E. Franchon, M. Laramas, and D. Charlety, Quelles attentes des patients souffrant de cancers en hôpital de jour en termes d'information sur leur traitement ?, 2010.

C. Rodrigo, E. , C. Martí, M. , N. Fontestad et al., Quality assessment of two pharmaceutical care models for onco-haematological patients. Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp, vol.31, pp.231-238, 2007.

E. M. Segal, J. Bates, S. L. Fleszar, L. M. Holle, and J. Kennerly-shah, Demonstrating the value of the oncology pharmacist within the healthcare team, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract, vol.25, issue.8, pp.1945-67, 2019.

A. D. Ruder, D. L. Smith, M. T. Madsen, and F. H. Kass, Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract, vol.17, issue.4, pp.425-457, 2011.

C. Chung, A. Collins, and N. Cui, Development and implementation of an interdisciplinary oncology program in a community hospital, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm, vol.68, issue.18, pp.1740-1747, 2011.

E. Sánchez-gómez, A. Prados, and Y. , Revisión de las interacciones farmacológicas de los fármacos antineoplásicos orales dispensados en un servicio de farmacia, Farm Hosp, vol.38, issue.4, pp.338-63, 2014.

A. Liekweg, M. Westfeld, M. Braun, O. Zivanovic, and T. Schink, Pharmaceutical care for patients with breast and ovarian cancer, Support Care Cancer, vol.20, issue.11, pp.2669-77, 2012.

F. Caracuel, Ú. Baños, M. D. Herrera, G. Ramírez, and N. Muñoz, Influence of pharmaceutical care on the delayed emesis associated with chemotherapy, Int J Clin Pharm, vol.36, issue.2, pp.287-90, 2014.

E. A. Hansen, J. M. Pietkiewicz, and B. L. Blum, Evaluation of the Feasibility and Utility of a Pharmacist-Centered Collaborative Drug Therapy Management Program for Oncology-Based Symptom Management, J Pharm Pract, vol.29, issue.3, pp.206-217, 2016.

Y. Wang, H. Wu, and F. Xu, Impact of Clinical Pharmacy Services on KAP and QOL in Cancer Patients: A Single-Center Experience, BioMed Res Int, pp.1-8, 2015.

L. A. Randolph, C. K. Walker, A. T. Nguyen, and S. R. Zachariah, Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract, vol.24, issue.1, pp.3-8, 2018.

M. France, A. Leromain, C. Jarre, M. Hellot-guersing, and C. Derharoutunian, Utilisation du dossier pharmaceutique en rétrocession : analyse de 5 mois d'expérimentation. Annales pharmaceutiques française, 2018.

A. Dony, T. Baum, A. Potier, S. Doerper, and V. Guillaume, Utiliser le dossier pharmaceutique pour concilier la capacité informationnelle du DP, Pharm Hosp Clin, vol.50, issue.3, pp.332-335, 2015.

D. Qu'est-ce-que-le, Dossier Pharmaceutique -Ordre National des Pharmaciens

D. Sur,

B. Loulière, M. Roudaut, S. Briançon, N. Thilly, and F. Empereur, Initiative des HIGH 5s Medication Reconciliation : Rapport d'expérimentation sur la mise en oeuvre de la conciliation des traitements médicamenteux par neuf établissements de santé français, HAS, vol.125, 2015.

E. Dufay, Sécuriser la prise en charge médicamenteuse du patient : les perspectives d'une autre performance

P. Blower, R. De-wit, S. Goodin, and M. Aapro, Drug-drug interactions in oncology: Why are they important and can they be minimized?, Crit Rev Oncol Hematol, vol.55, issue.2, pp.117-159, 2005.

J. H. Beijnen and J. H. Schellens, Drug interactions in oncology, Lancet Oncol, vol.5, issue.8, pp.489-96, 2004.

R. P. Riechelmann, F. Moreira, Ò. Smaletz, and E. D. Saad, Potential for drug interactions in hospitalized cancer patients, Cancer Chemother Pharmacol, vol.56, issue.3, pp.286-90, 2005.

R. P. Riechelmann and E. D. Saad, A Systematic Review on Drug Interactions in Oncology, Cancer Invest, vol.24, issue.7, pp.704-716, 2006.

J. B. Bossaer and C. M. Thomas, Drug Interaction Database Sensitivity With Oral Antineoplastics: An Exploratory Analysis, J Oncol Pract, vol.13, issue.3, pp.217-239, 2017.

B. Muluneh, M. Schneider, A. Faso, L. Amerine, and R. Daniels, Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program, J Oncol Pract, vol.14, issue.6, pp.324-358, 2018.

L. Chiffres,

D. Sur,

K. Gaertner, S. C. Lüer, M. Frei-erb, and K. Von-ammon, Complementary individual homeopathy in paediatric cancer care: A case series from a University Hospital, Complement Ther Med. déc, vol.41, pp.267-70, 2018.

R. M. Kline, C. Bazell, E. Smith, H. Schumacher, and R. Rajkumar, Centers for medicare and medicaid services: using an episode-based payment model to improve oncology care, J Oncol Pract, vol.11, issue.2, pp.114-120, 2015.

. Dgos, Expérimenter et innover pour mieux soigner

S. Ministère-des, L. De, and . Santé, , 2020.

I. Sainte-catherine and I. Paoli-calmettes, Appel à projet DGOS 2017 : Etude de l'impact clinique et médico-économique d'une organisation innovante de pharmacie clinique partagée au sein de 2 établissements de cancérologie intégrant un système d'assistance numérique personnalisé permettant la sécurisation de la délivrance

F. Oncolien and S. Palbociclib,

D. Sur,